Surprisingly, the serum biomarker PSA, which is typically increased in aggressive prostate cancers, was normal for most prostate SCC patients, and only 23.5% of patients had high PSA levels (>10 ng/mL). The gene discussed is KLK3; the disease is prostate carcinoma.